Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $56803.0.

  • BioNexus Gene Lab's Other Accumulated Expenses rose 1781.43% to $56803.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $56803.0, marking a year-over-year increase of 1781.43%. This contributed to the annual value of $50816.0 for FY2024, which is 4673.13% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Other Accumulated Expenses stood at $56803.0, which was up 1781.43% from $55809.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Other Accumulated Expenses' 5-year high stood at $56803.0 during Q3 2025, with a 5-year trough of -$16793.0 in Q1 2021.
  • In the last 5 years, BioNexus Gene Lab's Other Accumulated Expenses had a median value of $18566.0 in 2021 and averaged $28853.0.
  • As far as peak fluctuations go, BioNexus Gene Lab's Other Accumulated Expenses skyrocketed by 26648.13% in 2021, and later plummeted by 3653.99% in 2022.
  • Over the past 5 years, BioNexus Gene Lab's Other Accumulated Expenses (Quarter) stood at $18272.0 in 2021, then fell by 9.32% to $16569.0 in 2022, then soared by 109.02% to $34632.0 in 2023, then surged by 46.73% to $50816.0 in 2024, then increased by 11.78% to $56803.0 in 2025.
  • Its Other Accumulated Expenses was $56803.0 in Q3 2025, compared to $55809.0 in Q2 2025 and $52173.0 in Q1 2025.